New eczema pill shows promise in large Real-World trial

NCT ID NCT07276620

Not yet recruiting Disease control Sponsor: Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test the drug ivarmacitinib in 1,000 people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). Participants take a daily pill for up to 52 weeks, with the option to adjust the dose. Researchers will measure how well the drug clears skin rashes and reduces itching, and track any side effects. The goal is to see how well the drug works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivarmacitinib (a JAK inhibitor taken as a tablet)
What this could lead to: If successful, this could confirm ivarmacitinib as a safe and effective long-term treatment option for moderate-to-severe atopic dermatitis, helping more people manage their symptoms.
What could go wrong: This is a real-world study, not a blinded placebo trial, so results may be less definitive. Side effects of JAK inhibitors include infection risk and blood abnormalities, and the study is still recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

More trials for these conditions

Other studies related to the condition(s) this trial covers.